What is Still's Disease?
Still's disease is a single rare autoinflammatory disorder that affects both children (previously called systemic juvenile idiopathic arthritis/sJIA) and adults (previously called adult-onset Still's disease/AOSD), characterized by four cardinal features: spiking fever ≥39°C, transient salmon-pink rash, musculoskeletal involvement, and markedly elevated inflammatory markers. 1
Core Clinical Features
The 2024 EULAR/PReS guidelines provide operational definitions to facilitate rapid diagnosis 1:
Fever Pattern:
- Temperature ≥39°C (102.2°F)
- Spiking pattern lasting at least 7 days
- Often quotidian (daily) with return to baseline between spikes
Skin Manifestations:
- Transient, evanescent rash that coincides with fever spikes
- Salmon-pink (erythematous) appearance is typical
- Preferentially involves the trunk
- May present as urticarial variants
- Can be challenging to detect on darker skin tones
Musculoskeletal Involvement:
- Arthralgia and/or myalgia are usually present at onset
- Critical point: Overt arthritis is NOT required for diagnosis 1
- When arthritis develops, it typically appears 1 month after disease onset (range 0 to several months)
- Requiring arthritis for diagnosis causes unnecessary and potentially harmful diagnostic delays
Laboratory Hallmarks:
- Neutrophilic leukocytosis (elevated white blood cell count with high neutrophils)
- Markedly elevated ESR and CRP
- Very high serum ferritin levels (typically higher than other inflammatory conditions)
- Elevated platelet count, fibrinogen, and D-dimers
- Elevated liver function tests (LFTs) are common 1
Additional Common Features
Beyond the four cardinal manifestations 2, 3:
- Sore throat
- Lymphadenopathy
- Hepatomegaly and/or splenomegaly
- Serositis (pericarditis, pleuritis)
Historical Context and Nomenclature
The arbitrary age cutoff of 16 years that historically separated sJIA from AOSD was based on UK hospital department divisions in the mid-20th century, not biological differences 1. The 2024 EULAR/PReS guidelines now recognize these as one disease entity under the unified name "Still's disease" 1. This reflects the shared pathogenic mechanisms involving innate immune system activation with neutrophil and macrophage activation, driven by IL-1β, IL-6, and IL-18 3.
Life-Threatening Complications
Macrophage Activation Syndrome (MAS):
- The most severe and life-threatening complication 1
- More frequent in children under age 2, but can occur at any age
- Can present at disease onset, during treatment, or even during remission
- May be triggered by infection
- Requires immediate recognition and aggressive treatment
- Features multi-organ involvement and cytopenias 4
Lung Disease:
- Requires active screening with clinical symptoms (clubbing, persistent cough, shortness of breath)
- Pulmonary function tests (pulse oximetry, DLCO measurement)
- High-resolution CT scan when symptoms present 1
Disease Patterns
Three clinical patterns have been identified 2:
- Monocyclic: Single systemic episode
- Polycyclic: Multiple flares (≤1 year duration) alternating with remissions
- Chronic: Persistently active disease with associated polyarthritis
Diagnostic Approach
No single symptom or laboratory finding is specific for Still's disease 1. Diagnosis requires:
- Recognition of the characteristic constellation of clinical features
- Exclusion of infections, malignancies, and other rheumatological conditions
- Classification criteria (such as Yamaguchi criteria) can support diagnosis but were not specifically developed for diagnostic purposes 1
Emerging biomarkers that may aid diagnosis include IL-18 and S100 proteins, though these are not yet universally validated or available 1, 5, 6.
Treatment Goals
The ultimate therapeutic goal is drug-free remission, which is achievable in a substantial proportion of patients with modern therapies 1. Treatment follows a treat-to-target approach with sequential goals:
- Clinically inactive disease (CID)
- Remission (CID maintained for ≥6 months)
- Drug-free remission
Optimal first-line therapy involves early use of IL-1 or IL-6 inhibitors combined with short-duration glucocorticoids 1, 7, as these biologics show the highest level of evidence for efficacy and safety.
Key Clinical Pitfalls
- Do not delay diagnosis waiting for arthritis to develop - arthralgia alone is sufficient for diagnosis 1
- Always maintain high suspicion for MAS - monitor with adequate laboratory workups and be prepared to rapidly adjust treatment 1
- Avoid prolonged high-dose glucocorticoid monotherapy - early biologic therapy (IL-1 or IL-6 inhibition) is preferred to minimize steroid exposure 1, 7
- Screen for lung disease in all patients, particularly those with risk factors 1